Fig. 2

AGR2 mediated doxorubicin-sensitivity of breast cancer cells in vitro. a MCF-7 cells were stably transduced with a control shRNA vector or an AGR2-shRNA vector. b MCF-7 and c MDA-MB-231 cells were stably transduced with a control vector or an AGR2 over-expression vector. a-c Cells were analyzed for expression of AGR2 protein (left panel). Cells were analyzed for cell viability (middle panel), and viability of control was set as 100%. Cells were treated with doxorubicin for 48 h (right panel), followed by measuring for cell viability (n = 6), and viability of untreated cells was set as 100%. d MCF-7 cells, stably expressing a control shRNA vector or an AGR2-shRNA vector, were treated with doxorubicin (100 nM) for 48 h. Protein levels were detected by western blotting with indicated antibodies. Experiment was repeated three times. Data are shown as mean ± SD, compared using unpaired t test.*, p < 0.05; n.s., no significance